• Rapidly achieves high tear and corneal tissue concentrations 1,2,3,4
• Excellent performance against key isolates demonstrated by T.R.U.S.T surveillance data 7
• Susceptibility of key ocular isolates has remained high despite years of widespread levofloxacin use 6,11,12
• Broad Spectrum coverage against gram positive without compromise on coverage of the key gram negative pathogens 5,6,7, 8,10,11,12
• Excellent in vitro coverage of P. Aeruginosa and Strep. Pneumoniae 7,8
• Levofloxacin has minimal cytotoxicity to both human corneal endothelial cells nd keratocytes 9
• Can be used in children of 1 year old and above
• Neutral pH makes Oftaquix safe and comfortable for the patient

References:
1. Akkan AG et al Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin and norfloxacin in human eyes. Int J Clin Pharmacol Ther 1998;35(5):214-217
2. Raizman MB et al, Tear concentrations of levofloxacin following topical administration
of a single dose of 0.5% Levofloxacin ophthalmic solution in healthy volunteers. Clinical Therapeutics 2002; 24(9); 1439-1450
3. Mitsui Y et al AQCmax as a pharmacokinetic parameter of ophthalmics solution J Eye 1995 12:783-786
4. Kowolski RP et al, Gatifloxacin and moxifloxacin; A in vitro study susceptibility
comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis
isolates Am J Ophthalmol 2003;136:500-505
5. Kresken M; Multicenter study to determine prevalence of resistance among isolates of various bacterial pathogens against antibiotics obtained from patients with eye
infections in Germany. Chemother J 2007;16:49-59.
6. Data on file Vistakon Pharmaceuticals In vitro activity of levofloxacin against clinically relevant bacterial isolates from eye infection sources.
7. Data on file Vistakon Pharmaceuticals; Antimicrobial susceptibility; nationwide
patterns in the T.R.U.S.T surveillance program.
8. Emerging trends in antibiotic resistance strategies for appropriate antibiotic use,. Formulary 2005;40 (suppl 1) 3-15
9. Skelnik DL, Clark LA Bezwada P In vitro effect of drug concentration and exposure time of levofloxacin, ofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin on human corneal endothelial cells and keratocytes. Presented at ARVO Annual meeting Fort Lauderdale May 4-9 2003. Poster #4739
10. PDR (Physicians Desk Reference) 2004 (Quixin)
11. In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones. Graves A, Henry
M, O'Brien TP, Hwang DG, Van Buskirk A, Trousdale MD Cornea. 2001–20(3):301-5.
12. Lichtenstein SJ, Rinehart M and the Levofloxacin Bacterial Cconjunctivitis Study Group J AAPOS 2003;7:317-324